Modified Candela Family of Pulsed Dye Lasers 510k Summary KO0S007 2, p . } of 2.
= JUN 13 2005
510(k) Summary
This 510(k) is to provide notification of substantial equivalence for the Candela Family of Pulsed
Dye Lasers which is substantially equivalent to previously marketed devices indicted for the
following uses:
General Surgery: Photocoagulation of benign cutaneous vascular lesions and benign
cutaneous lesions.
. Dermatology/Plastic Surgery: For treatment of benign cutaneous vascular lesions, such as
facial and leg telangiectasia, rosacea, port wine stains, hemangiomas, angioma, spider
- angioma, Poikiloderma of Civatte, and benign cutaneous lesions, such as warts, scars,

striae and psoriasis and the treatment of wrinkles. Treatment of Benign Epidermal
Pigmented Lesions. Treatment of Inflammatory Acne Vulgaris
Gynecology: Photocoagulation of benign cutaneous lesions and benign vascular lesions in
gynecology.
Podiatry: Treatment of benign cutaneous lesions, such as warts.
Submitted by: Candela Corporation

530 Boston Post Road

Wayland, MA 01778-1886
Contact Person: Lorraine Calzetta
Date prepared: March 11, 2005
Classification: Class II (21 CFR § 878.4810 Laser Surgical! Instrument for use

in General and Plastic Surgery and in Dermatology)
Common Name: Dermatology Laser, Candela Family of Pulse Dye Laser Systems

Predicate Devices:

Candela Family of Pulsed Dye Lasers - K043251

Cynosure VStar (Tristar PDL) - K033176, K032565
Description:
The Candela Family of Pulsed Dye Laser Systems are 585, 595nm flash-lamp excited pulse dye
medical lasers, indicated for the following uses:
Genera! Surgery: Photocoagulation of benign cutaneous vascular lesions and benign
cutaneous lesions.

wy
01

Modified Candela Family of Pulsed Dye Laser Systems 510(k) Summary KOS Col 3, P 2. Lor 2?

é
Summary cont.
Dermatology/Plastic Surgery: For treatment of benign cutaneous vascular lesions, such as
facial and leg telangiectasia, rosacea, port wine stains, hemangiomas, angioma, spider
angioma, Poikiloderma of Civatte, and benign cutaneous lesions, such as warts, scars,
striae and psoriasis and the treatment of wrinkles. Treatment of Benign Epidermal
Pigmented lesions. Treatment of Inflammatory Acne Vulgaris

_. Gynecology: Photocoagulation of benign cutaneous lesions and benign vascular lesions in
gynecology.
Podiatry: Treatment of benign cutaneous lesions, such as warts.
The laser output energy is delivered via an optical fiber to a handpiece, which produces circular
beams with diameters of 35, 7 or 10, 12 or 3x10 millimeters on the skin..
The Candela Family of Pulsed Dye Laser Systems is equipped with safety interlock systems to
protect patients and operators. Users of the device make selections from an onboard control
panel to regulate operation during treatment.
Asa laser product, the Candela Family of Pulsed Dye Laser Systems conforms to the CDRH
Laser Performance Standard (21 CFR 1040). In addition the laser conforms to UL/IEC 60601-1.
Electrical Safety Standard.
Summary of Substantial Equivalence:
The Candela Family of Pulsed Dye Laser Systems, has the same intended use, utilizes similar
operating principles and matches key design aspects, as the predicate devices.
On the basis of similarities in methods of assembly, method of operation, and intended uses,
Candela Corporation believes that its Candela Family of Pulsed Dye Laser Systems is
substantially equivalent to the predicate devices.

ey
j DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service
Lg mmeroewnemenneee
“one Food ahd Drug Administration
9200 Corporate Boulevard
Rockville MD 20850
JUN 13 2005 ;
Ms. Lorraine Calzetta
Manager, Regulatory Affairs
Candela Corporation
530 Boston Post Road
Wayland, Massachusetts 01778
Re: K050673
Trade/Device Name: Candela Family of Pulsed Dye Laser Systems
Regulation Number: 21. CFR 878.4810
Regulation Name: Laser surgical instrument for use in general and
plastic surgery and in dermatology
Regulatory Class: II .
Product Code: GEX
Dated: March 11, 2005
Received: March 15, 2005
Dear Ms. Calzetta:
We have reviewed your Section 510(k) premarket notification of intent to market the device
referenced above and have determined the device is substantially equivalent (for the indications
for use stated in the enclosure) to legally marketed predicate devices marketed in interstate
commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to
devices that have been reclassified in accordance with the provisions of the Federal Food, Drug,
and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA).
You may, therefore, market the device, subject to the general controls provisions of the Act. The
general controls provisions of the Act include requirements for annual registration, listing of
devices, good manufacturing practice, labeling, and prohibitions against misbranding and
adulteration.
If your device is classified (see above) into either class II (Special Controls) or class II] (PMA), it
may be subject to such additional controls. Existing major regulations affecting your device can
be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may
publish further announcements concerning your device in the Federal Register.
Please be advised that FDA’s issuance of a substantial equivalence determination does not mean
that FDA has made a determination that your device complies with other requirements of the Act
or any Federal statutes and regulations administered by other Federal agencies. You must
comply with all the Act’s requirements, including, but not limited to: registration and listing (21
CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set
forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic
product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Page 2 - Ms. Lorraine Calzetta This letter will allow you to begin marketing your device as described in your Section 510(k) .
premarket notification. The FDA finding of substantial equivalence of your device to a legally
marketed predicate device results in a classification for your device and thus, permits your device
to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please
contact the Office of Compliance at (240) 276-0115. Also, please note the regulation entitled,
"Misbranding by reference to premarket notification” (21CFR Part 807.97). You may obtain
other general information on your responsibilities under the Act from the Division of Small
Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or
(301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

LE
“9 Miriam C. Provost, Ph.D.
Acting Director
Division of General, Restorative
and Neurological Devices

Office of Device Evaluation

Center for Devices and Radiological Health
Enclosure

Indications for Use .
510(k) Number (if known): KO 5 O67 2
Device Name: Candela Family of Pulsed Dye Laser Systems
Indications For Use: ,
The Candela Family of Pulse Dye Laser Systems is indicated for the following uses :
General Surgery: Photocoagulation of benign cutaneous vascular lesions and benign
cutaneous lesions. Dermatology/Plastic Surgery: For treatment of benign cutaneous vascular lesions, such as facial
and leg telangiectasia, rosacea, port wine stains, hemangiomas, angioma, spider angioma,
Poikiloderma of Civatte, and benign cutaneous lesions, such as warts, scars, striae and
psoriasis and the treatment of wrinkles. Treatment of Benign Epidermal Pigmented Lesions.
Treatment of Inflammatory Acne Vulgaris
Gynecology: Photocoagutation of benign cutaneous lesions and benign vascular lesions in
gynecology.
Podiatry: Treatment of benign cutaneous lesions, such as warts.
Prescription Use _X AND/OR Over-The-Counter Use
(Part 21 CFR 801 Subpart D) (21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF
NEEDED)
TT
Concurrence of CDRH, Office of Device Evaluation (ODE)
Lik

Lom Sgt Sit

(Sivision © oe gestorative Page 1 of _|{

a Gey OF RET hs 8”

_ ag Neurological Dev ee

. kK os Oo a)

